The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study-Reference-Cited by-同舟云学术

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

Published:2018-11-14 Issue:1 Volume:25 Page:33-44
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Oldenburg Johannes¹^ORCID,Mahlangu Johnny N.²^ORCID,Bujan Willem³,Trask Peter⁴,Callaghan Michael U.⁵^ORCID,Young Guy⁶^ORCID,Asikanius Elina⁷,Peyvandi Flora⁸^ORCID,Santagostino Elena⁸,Kruse-Jarres Rebecca⁹^ORCID,Negrier Claude¹⁰,Kessler Craig¹¹,Xu Jin⁴,Windyga Jerzy¹²^ORCID,Shima Midori¹³,von Mackensen Sylvia¹⁴^ORCID

Affiliation:

1. Department of Experimental Haematology and Transfusion Medicine; Universitätsklinikum University Clinic Bonn; Bonn Germany

2. Haemophilia Comprehensive Care Centre, Faculty of Health Sciences; University of the Witwatersrand and NHLS; Johannesburg South Africa

3. Instituto de Costarricense de Investigaciones Científicas; San Jose Costa Rica

4. Genentech, Inc.; South San Francisco California

5. Children’s Hospital of Michigan; Detroit Medical Center; Detroit Michigan

6. Children’s Hospital Los Angeles; University of Southern California Keck School of Medicine; Los Angeles California

7. F. Hoffmann-La Roche Ltd; Basel Switzerland

8. IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico; Milan Italy

9. Washington Center for Bleeding Disorders at BloodWorks NW; University of Washington; Seattle Washington

10. Louis Pradel University Hospital; Lyon France

11. Georgetown University Medical Center, N.W.; Washington District of Columbia

12. Department of Disorders of Hemostasis and Internal Medicine; Institute of Hematology and Transfusion Medicine; Warsaw Poland

13. Department of Pediatrics; Nara Medical University; Kashihara Japan

14. University Medical Centre Hamburg-Eppendorf; Hamburg Germany

Funder

Roche

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13618/fullpdf

Reference43 articles.

1. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy;Kingdon;Biotechnol Appl Biochem,2002

2. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life;Khawaji;Eur J Haematol,2012

3. Future of coagulation factor replacement therapy;Peyvandi;J Thromb Haemost,2013

4. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

5. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study;Gouw;Blood,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country;Clinical and Applied Thrombosis/Hemostasis;2024-01

2. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab;Journal of Thrombosis and Haemostasis;2024-01

3. Cost‐effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India;Haemophilia;2023-12-26

4. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis;Expert Review of Hematology;2023-12-02

5. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan;Haemophilia;2023-10-11